=> file caplus
FILE 'CAPLUS' ENTERED AT 14:03:54 ON 12 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 12 Oct 2004 VOL 141 ISS 16
FILE LAST UPDATED: 11 Oct 2004 (20041011/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L3 17 SEA FILE=REGISTRY SSS FUL L1
L4 3 SEA FILE=CAPLUS L3

=> d l4 1-3 ibib abs hitstr

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:589362 CAPLUS
DOCUMENT NUMBER: 141:140426
TITLE: Preparation of 2-arylthiazole derivatives as KCNQ modulators
INVENTOR(S): Boy, Kenneth M.; Wu, Yong-Jin; Guernon, Jason M.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004060281 A2 20040722 WO 2003-US39351 20031211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2004147401 A1 20040729 US 2003-731854 20031209
PRIORITY APPLN. INFO.: US 2002-435970P P 20021220
OTHER SOURCE(S): MARPAT 141:140426
GI



AB Title compds. I (Q1 = CH, N; Ar1 = Ph, pyridyl, etc.: R1 = H, alkyl, hydroxymethyl, CF3; R2 = halo, alkyl, perfluoroalkyl, alkoxy, perfluoroalkoxy, amino; R3 = H, halo, alkoxy) are prepared Thus, stirring 2-phenyl-4-trifluoromethylthiazole-5-carboxylic acid with 1-(3-trifluoromethoxyphenyl)ethylamine in DMF in the presence of PyBOP, DMAP, and Et3N at 25° for 18 h gave 42% 2-phenyl-4-trifluoromethylthiazole-5-carboxylic acid [1-(3-trifluoromethoxyphenyl)ethyl]amide. I are openers of KCNQ potassium channels and are useful in the treatment of disorders that are responsive to the opening of the KCNQ potassium channels, including pain and migraine.

IT **725248-16-8P 725248-26-0P 725248-27-1P**
725248-28-2P 725248-71-5P 725248-72-6P
725248-75-9P 725248-76-0P 725248-77-1P
725249-90-1P 725249-92-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylthiazole derivs. as KCNQ modulators)

RN 725248-16-8 CAPLUS

CN 5-Thiazolecarboxamide, 2-[3-[(diethylamino)methyl]-2-pyridinyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 725248-26-0 CAPLUS
CN 5-Thiazolecarboxamide, 2-[3-[(diethylamino)methyl]-2-pyridinyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 725248-27-1 CAPLUS
CN 5-Thiazolecarboxamide, 2-[3-[[ethyl(1-methylethyl)amino]methyl]-2-pyridinyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 725248-28-2 CAPLUS
CN 5-Thiazolecarboxamide, 2-(3-methyl-2-pyridinyl)-N-[(1S)-1-[3-(3-pyridinyl)phenyl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725248-71-5 CAPLUS
CN 5-Thiazolecarboxamide, 2-(3-methyl-2-pyridinyl)-N-[(1S)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725248-72-6 CAPLUS
CN 5-Thiazolecarboxamide, 2-[3-(1,3-dioxolan-2-yl)-2-pyridinyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 725248-75-9 CAPLUS
CN 5-Thiazolecarboxamide, 2-[3-[(ethylpropylamino)methyl]-2-pyridinyl]-N-[(1S)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725248-76-0 CAPLUS
CN 5-Thiazolecarboxamide, 2-[3-[[ethyl(4-pyridinylmethyl)amino]methyl]-2-pyridinyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 725248-77-1 CAPLUS
CN 5-Thiazolecarboxamide, 2-[3-(4-morpholinylmethyl)-2-pyridinyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 725249-90-1 CAPLUS
CN 5-Thiazolecarboxamide, 2-[3-[[ethyl(4-pyridinylmethyl)amino]methyl]-2-pyridinyl]-N-[(1S)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725249-92-3 CAPLUS
CN 5-Thiazolecarboxamide, 2-[3-[[ethyl(4-pyridinylmethyl)amino]methyl]-2-pyridinyl]-N-[1-[3-(4-morpholinylmethyl)phenyl]ethyl]-4-(trifluoromethyl)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:793403 CAPLUS
DOCUMENT NUMBER: 137:310931
TITLE: Preparation of phenylalkanoic acid derivatives as preventive or remedial agents for digestive tract diseases
INVENTOR(S): Horizoe, Tatsuo; Shinoda, Masanobu; Emori, Eita; Matsuura, Fumiyoshi; Kaneko, Toshihiko; Ohi, Norihito; Kasai, Shunji; Yoshitomi, Hideki; Yamazaki, Kazuto; Miyashita, Sadakazu; Hihara, Taro; Seiki, Takashi; Clark, Richard; Harada, Hitoshi
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 344 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002080899	A1	20021017	WO 2002-JP3006	20020327

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: JP 2001-101465 A 20010330
JP 2001-105131 A 20010403
OTHER SOURCE(S): MARPAT 137:310931
GI



I

AB Disclosed is a preventive/remedy for digestive tract or inflammatory diseases, which contains as the active ingredient a novel carboxylic acid derivative represented by the following formula [I; R1 = H, OH, each (un)substituted C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 hydroxyalkyl, C1-6 hydroxyalkoxy, C1-6 hydroxyalkylthio, C1-6 aminoalkyl, C1-6 aminoalkoxy, C1-6 aminoalkylthio, C2-12 alkoxyalkyl, C3-7 cycloalkyl, C3-7 cycloalkyloxy, C3-7 cycloalkylthio, C2-6 alkenyl, C2-6 alkenyloxy, or C2-6 alkenylthio, etc.; L = a single or double bond, each (un)substituted C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene; M = a single bond, each (un)substituted C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene; T = a single bond, each (un)substituted C1-3 alkylene, C2-3 alkenylene, or C2-3 alkynylene; W = 2,4-dioxothiazolidin-5-yl, 2,4-dioxothiazolidin-5-ylidene, carboxy, (un)substituted CONH2; X = O, (un)substituted C2-6 alkenylene, hydroxymethylene, CO, CS, N-(un)substituted CQNH, NHCQ, SO2NH, NHSO2, or NHCQNH (Q = O, S); Y = (un)substituted C5-12 aromatic hydrocarbyl or C3-7 aliphatic hydrocarbyl optionally containing ≥1 heteroatoms; ring Z = C5-6 aromatic hydrocarbyl; Y = (un)substituted aromatic hydrocarbon group optionally containing ≥1 heteroatoms; some provisos given], a salt of the derivative, or a hydrate of either. The above digestive tract diseases include (1) inflammatory digestive tract diseases such as ulcerous colitis, Crohn's disease, pancreatitis, and gastritis, (2) digestive tract proliferative diseases such as digestive tract benign rumors, digestive tract polyp, hereditary (genetic) polyposis syndromes, colon cancer, rectum cancer, and stomach cancer, and (3) digestive tract ulcerous diseases such as duodenal ulcer, stomach ulcer, esophagus ulcer, regurgitant esophagitis, stress ulcer or erosion, erosion caused by drugs, and Zollinger-Ellison syndromes. The above inflammatory diseases include arthritic rheumatism, multiple sclerosis, immunodeficiency, cachexia, osteoarthritis, osteoporosis, asthma, and allergy. The compds. I are triple agonists for PPAR (peroxisome proliferator-activated receptor) α, β, and γ subtype. Thus, 2-isopropoxy-3-[4-methoxy-3-[[[4-(trifluoromethyl)benzyl]amino]carbonyl]phenyl]propanoic acid in vitro showed the transcription activity for PPARα, β, and γ with EC50 of 0.08, 2.513, and 0.382 μM, resp., in CV-1 cell. (2S)-3-[3-[[(2,4-dichlorobenzoyl)amino]methyl]-4-methoxyphenyl]-2-isopropoxypropanoic acid at 1 mg/kg/day p.o. for 3 days showed a disease activity index based on diarrhea, bloody excrement, and weight loss (DAI) of 2.0±0.3 in mice suffering from colitis induced by dextran sulfate sodium salt vs. 2.8±0.2 for the control group and 2.1±0.3 for the

mice treated with rosiglitazone at 30 mg/kg/day. Many compds. prepared do not possess the thiazolidine skeleton and thereby may completely avoid toxicity such as liver disorder which was noted in the past as a problem for compds. having PPARγ agonist activity.

IT **472805-98-4P 472806-14-7P 472806-57-8P 472806-69-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylalkanoic acid derivs. as peroxisome proliferator-activated receptor agonists and remedial or preventive agents for digestive tract or inflammatory diseases)

RN 472805-98-4 CAPLUS
CN Benzenepropanoic acid, 4-methoxy-α-(1-methylethoxy)-3-[[[[4-methyl-2-(3-methyl-2-pyridinyl)-5-thiazolyl]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 472806-14-7 CAPLUS
CN Benzenepropanoic acid, 4-methoxy-α-(1-methylethoxy)-3-[[[[4-methyl-2-(5-methyl-2-pyridinyl)-5-thiazolyl]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 472806-57-8 CAPLUS
CN Benzenepropanoic acid, 3-[[[[4-ethyl-2-(3-methyl-2-pyridinyl)-5-thiazolyl]carbonyl]amino]methyl]-4-methoxy-α-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 472806-69-2 CAPLUS
CN Benzenepropanoic acid, 3-[[[[4-ethyl-2-(5-methyl-2-pyridinyl)-5-thiazolyl]carbonyl]amino]methyl]-4-methoxy-α-(1-methylethoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:416920 CAPLUS
DOCUMENT NUMBER: 135:19630
TITLE: Preparation of substituted oxazoles and thiazoles as hPPAR alpha activators
INVENTOR(S): Sierra, Michael Lawrence
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001040207	A1	20010607	WO 2000-EP11995	20001130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
TW 555753	B	20031001	TW 2000-89125344	20001129
BR 2000016067	A	20020806	BR 2000-16067	20001130
TR 200201473	T2	20020923	TR 2002-200201473	20001130
EP 1244642	A1	20021002	EP 2000-983189	20001130
EP 1244642	B1	20040428		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AU 758758	B2	20030327	AU 2001-20030	20001130
JP 2003515597	T2	20030507	JP 2001-541891	20001130
AT 265442	E	20040515	AT 2000-983189	20001130
NO 2002002467	A	20020726	NO 2002-2467	20020524
US 6518290	B1	20030211	US 2002-148765	20020531

ZA 2002004241 A 20030702 ZA 2002-4241 20020728
PRIORITY APPLN. INFO.: GB 1999-28561 A 19991202
GB 2000-3500 A 20000215
WO 2000-EP11995 W 20001130
OTHER SOURCE(S): MARPAT 135:19630
GI



I



II

AB The title compds. [I; X1 = O, S; R1, R2 = H, halo, Me, OMe; n = 1-2; X2 = NH, NMe, O; one of Y and Z = N, and the other = O, S; R3 = (un)substituted Ph, pyridyl (wherein the N is in position 2 or 3) with the provision that when R3 = pyridyl, the N is unsubstituted; R4 = CF3, Me] and their pharmaceutically acceptable salts, useful as a selective hPPAR α agonists, were prepared E.g., a multi-step synthesis of the ester II was given. Biol. data for compds. I were presented.

IT **343322-38-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted oxazoles and thiazoles as hPPAR alpha activators)

RN 343322-38-3 CAPLUS

CN Propanoic acid, 2-methyl-2-[4-[[[[4-methyl-2-[5-(trifluoromethyl)-2-pyridinyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



IT **343322-39-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted oxazoles and thiazoles as hPPAR alpha activators)
RN 343322-39-4 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[[4-methyl-2-[5-(trifluoromethyl)-2-pyridinyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => file uspatall

FILE 'USPATFULL' ENTERED AT 14:04:40 ON 12 OCT 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:04:40 ON 12 OCT 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> d que
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L3 17 SEA FILE=REGISTRY SSS FUL L1
L5 2 SEA L3

=> d l5 1-2 ibib abs hitstr

L5 ANSWER 1 OF 2 USPATFULL on STN
ACCESSION NUMBER: 2004:190628 USPATFULL
TITLE: 2-aryl thiazole derivatives as KCNQ modulators
INVENTOR(S): Boy, Kenneth M., Durham, CT, UNITED STATES
Wu, Yong-Jin, Madison, CT, UNITED STATES
Guernon, Jason M., Hamden, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004147401	A1	20040729
APPLICATION INFO.:	US 2003-731854	A1	20031209 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-435970P	20021220 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 2064
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel 2-arylthiazole derivatives of Formula I are described which are openers of KCNQ potassium channels and are useful in the treatment of disorders that are responsive to the opening of the KCNQ potassium channels, including pain and migraine. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **725248-16-8P 725248-26-0P 725248-27-1P**
725248-28-2P 725248-71-5P 725248-72-6P
725248-75-9P 725248-76-0P 725248-77-1P
725249-90-1P 725249-92-3P
(preparation of arylthiazole derivs. as KCNQ modulators)

RN 725248-16-8 USPATFULL
CN 5-Thiazolecarboxamide, 2-[3-[(diethylamino)methyl]-2-pyridinyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 725248-26-0 USPATFULL
CN 5-Thiazolecarboxamide, 2-[3-[(diethylamino)methyl]-2-pyridinyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 725248-27-1 USPATFULL
CN 5-Thiazolecarboxamide, 2-[3-[[ethyl(1-methylethyl)amino]methyl]-2-pyridinyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 725248-28-2 USPATFULL
CN 5-Thiazolecarboxamide, 2-(3-methyl-2-pyridinyl)-N-[(1S)-1-[3-(3-pyridinyl)phenyl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725248-71-5 USPATFULL
CN 5-Thiazolecarboxamide, 2-(3-methyl-2-pyridinyl)-N-[(1S)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725248-72-6 USPATFULL
CN 5-Thiazolecarboxamide, 2-[3-(1,3-dioxolan-2-yl)-2-pyridinyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 725248-75-9 USPATFULL
CN 5-Thiazolecarboxamide, 2-[3-[(ethylpropylamino)methyl]-2-pyridinyl]-N-[(1S)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725248-76-0 USPATFULL
CN 5-Thiazolecarboxamide, 2-[3-[[ethyl(4-pyridinylmethyl)amino]methyl]-2-pyridinyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 725248-77-1 USPATFULL
CN 5-Thiazolecarboxamide, 2-[3-(4-morpholinylmethyl)-2-pyridinyl]-4-(trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 725249-90-1 USPATFULL
CN 5-Thiazolecarboxamide, 2-[3-[[ethyl(4-pyridinylmethyl)amino]methyl]-2-pyridinyl]-N-[(1S)-1-[3-(4-morpholinyl)phenyl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725249-92-3 USPATFULL
CN 5-Thiazolecarboxamide, 2-[3-[[ethyl(4-pyridinylmethyl)amino]methyl]-2-pyridinyl]-N-[1-[3-(4-morpholinylmethyl)phenyl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L5 ANSWER 2 OF 2 USPATFULL on STN

ACCESSION NUMBER:	2003:40698 USPATFULL
TITLE:	Substituted oxazoles and thiazoles derivatives as HPPAr alpha activators
INVENTOR(S):	Sierra, Michael Lawrence, GlaxoSmithKline, Five Moore Dr., P.O. Box 13398, Research Triangle Park, NC, United States 27709

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6518290	B1	20030211	
	WO 2001040207		20010607	
APPLICATION INFO.:	US 2002-148765		20020531	(10)
	WO 2000-EP11995		20001130	

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-28561	19991202
	GB 2000-3500	20000215

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Stockton, Laura L.

LEGAL REPRESENTATIVE: Brink, Robert H.
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2166
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of formula (I) and pharmaceutically acceptable salts, solvates and hydrolysable esters thereof ##STR1##

wherein;

X.sub.1 represents O or S;

R.sup.1 and R.sup.2 independently represent H, halogen, --CH.sub.3 and --OCH.sub.3;

n represents 1 or 2;

X.sub.2 represents NH, NCH.sub.3 or O;

One of Y and Z is N, and the other is O or S;

R.sup.3 represents phenyl or pyridyl (wherein the N is in position 2 or 3) and is optionally substituted by one or more halogen, NO.sub.2, NH.sub.2, CF.sub.3, OCF.sub.3, OC.sub.1-6 straight or branched alkyl, C.sub.1-6 straight or branched alkyl, alkenyl or alkynyl with the provision that when R.sup.3 is pyridyl, the N is unsubstituted;

R.sup.4 represents CF.sub.3 or CH.sub.3

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **343322-38-3P**
(preparation of substituted oxazoles and thiazoles as hPPAR alpha activators)

RN 343322-38-3 USPATFULL

CN Propanoic acid, 2-methyl-2-[4-[[[[4-methyl-2-[5-(trifluoromethyl)-2-pyridinyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



IT **343322-39-4P**
(preparation of substituted oxazoles and thiazoles as hPPAR alpha activators)

RN 343322-39-4 USPATFULL

CN Propanoic acid, 2-methyl-2-[4-[[[[4-methyl-2-[5-(trifluoromethyl)-2-pyridinyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



=>